Study points to new method for accurately identifying Cannabis cultivars

A recent study published in the Journal of Cannabis Research highlights that integrating genetic markers with chemical analysis is highly effective for the precise identification of Cannabis cultivars. The study aims to address critical quality control challenges in the pharmaceutical industry.

The main objective is to ensure reproducibility and safety of batches intended for therapeutic use. Thus, the new methodology seeks to overcome the limitations of traditional classifications applied to Cannabis cultivars.

Methodology applied to Cannabis cultivars

To conduct the study, researchers used molecular markers of the SSR (simple sequence repeat) type combined with high-performance liquid chromatography (HPLC). The focus was on characterizing three distinct clonal Cannabis cultivars.

The analyzed samples had high THC content and were provided by SOMAI Pharmaceuticals. The analysis aimed to deepen the understanding of the exact composition of these plants for medicinal purposes.

Genetic and chemical differentiation of cannabis

The results showed that, although the chemical profiles of cannabinoids were similar among Cannabis cultivars — with THC exceeding 80% after purification — the genetics revealed unique differences.

Specific markers, such as ANUCS303 and C11CANN1, allowed for a clear differentiation. This enabled establishing a unique identity for each plant analyzed in the study.

Integration with chemical analysis and medicinal use of cannabis

While the Scientific Reports study focuses on geographical and forensic differentiation, other research published in 2026 expands the use of genetics to ensure patient safety. A recent article from the Journal of Cannabis Research points out that integrating genetic markers with chemical analysis is essential for the pharmaceutical industry.

In this survey, scientists were able to differentiate clonal Cannabis cultivars with high THC content that, chemically, appeared identical. The study reinforces that relying solely on cannabinoid analysis (chemotype) is not sufficient for rigorous quality control.

By cross-referencing DNA data (genotype) with the chemical profile, a robust "identity fingerprint" is created. This dual methodology aims to ensure that batches of cannabis-based medicines always maintain the same therapeutic efficacy, surpassing the natural variability of the plant that can affect treatment.

Importance of the "identity fingerprint" of cannabis plants

The study warns that commercial labels often fail to reflect the exact composition due to the high heterozygosity of the species. Genetic variability can influence the presence of minor cannabinoids and impurities in Cannabis cultivars.

This occurs even when the main components appear identical in standard chemical tests. Therefore, validating genetic identity, combined with the chemical profile, establishes a necessary "identity fingerprint".

The conclusion indicates that this methodology is crucial for the sector. It ensures therapeutic equivalence between batches and meets the stringent regulatory requirements for medicines based on Cannabis cultivars.